GDP (gemcitabine, dexamethasone, cisplatin) salvage therapy results in superior progression free survival compared to mini-beam prior to autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma.

被引：1
|
作者：
Kuruvilla, J [1 ]
Nagy, T [1 ]
Pintilie, M [1 ]
Keating, A [1 ]
Crump, M [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Blood & Marrow Transplant Program, Toronto, ON, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.905.905
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
905
引用
收藏
页码：258A / 259A
页数：2
相关论文
共 50 条
  • [31] Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial
    Byeong-Bae Park
    Won Seog Kim
    Cheolwon Suh
    Dong-Yeop Shin
    Jeong-A Kim
    Hoon-Gu Kim
    Won Sik Lee
    Annals of Hematology, 2015, 94 : 1845 - 1851
  • [32] Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma
    Santoro, Armando
    Mazza, Rita
    Pulsoni, Alessandro
    Re, Alessandro
    Bonfichi, Maurizio
    Zilioli, Vittorio Ruggero
    Salvi, Flavia
    Anastasia, Antonella
    Luminari, Stefano
    Gotti, Manuel
    Peli, Annalisa
    Liberati, Anna Marina
    Di Renzo, Nicola
    Castagna, Luca
    Giordano, Laura
    Carlo-Stella, Carmelo
    BLOOD, 2018, 132
  • [33] Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma
    Desai, Sanjal H.
    Spinner, Michael A.
    David, Kevin
    Bachanova, Veronika
    Goyal, Gaurav
    Kahl, Brad
    Dorritie, Kathleen
    Azzi, Jacques
    Kenkre, Vaishalee P.
    Arai, Sally
    Chang, Cheryl
    Fusco, Brendon
    Sumransub, Nuttavut
    Hatic, Haris
    Saba, Raya
    Ibrahim, Uroosa
    Harris, Elyse, I
    Shah, Harsh
    Murphy, Jacob
    Ansell, Stephen
    Jagadish, Deepa
    Orellana-noia, Victor
    Diefenbach, Catherine
    Iyenger, Siddharth
    Rappazzo, K. C.
    Mishra, Rahul
    Choi, Yun
    Nowakowski, Grzegorz S.
    Advani, Ranjana H.
    Micallef, Ivana N.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : 464 - 471
  • [34] Long Term Disease Free Survival and Survival of Patients with Relapsed Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplantation
    Abedrabo, Sabree
    Rodriguez, Tulio E.
    Klein, Leonard M.
    Bitran, Jacob
    BLOOD, 2023, 142
  • [35] Dexamethasone, high-dose ara-c, cisplatin and G-CSF (DHAP) prior to intensive therapy with stem cell support in relapsed or refractory Hodgkin lymphoma.
    Josting, A
    Rudolph, C
    Mapara, M
    Rueffer, U
    Von Schilling, C
    Doerken, B
    Diehl, V
    Engert, A
    BLOOD, 2000, 96 (11) : 240B - 240B
  • [36] Cyclophosphamide, Gemcitabine, Vinorelbine and Prednisone (CGEV) As Salvage Therapy for Relapsed or Refractory Hodgkin's Lymphoma before Hematopoietic Stem Cell Transplantation: A Single Center Experience
    Cardenas-Araujo, Daniela
    Judith Gonzalez-Leal, Xitlaly
    Gomez-Almaguer, David
    BLOOD, 2015, 126 (23)
  • [37] Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL)
    Broeckelmann, Paul J.
    Mueller, Horst
    Casasnovas, Olivier
    Hutchings, Martin
    von Tresckow, Bastian
    Borchmann, Peter
    Moskowitz, Craig
    Engert, Andreas
    BLOOD, 2015, 126 (23)
  • [38] Prognostic factors, clinical outcome and survival of patients with relapsed or refractory Hodgkin's lymphoma after autologous stem cell transplantation
    Gaudio, F.
    Pastore, D.
    Delia, M.
    Perrone, T.
    Curci, P.
    Laddaga, F. E.
    Specchia, G.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S435 - S435
  • [39] BEAM-Modified Conditioning Therapy with Cisplatin plus Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma
    Lucia Ron-Magana, Ana
    Eduardo Fernandez-Vargas, Omar
    Barrera-Chairez, Esperanza
    Silvestre Ron-Guerrero, Carlos
    Jaqueline Banuelos-Avila, Ana
    ANNALS OF TRANSPLANTATION, 2019, 24 : 584 - 587
  • [40] POST TRANSPLANT OUTCOMES IN A MULTICENTER PHASE II STUDY OF BRENTUXIMAB VEDOTIN AS FIRST LINE SALVAGE THERAPY IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
    Herrera, A.
    Palmer, J.
    Martin, P.
    Armenian, S.
    Tsai, N. -C.
    Mott, M.
    Sahebi, F.
    Cai, J. -L.
    Siddiqi, T.
    Popplewell, L.
    Nademanee, A.
    Rosen, S.
    Kwak, L.
    Forman, S.
    Chen, R.
    HAEMATOLOGICA, 2016, 101 : 47 - 48
12345